表紙
市場調查報告書
商品編碼
974083

全球急性缺血性腦中風治療藥市場:2020年∼2024年

Global Acute Ischemic Stroke Therapeutics Market 2020-2024

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球急性缺血性腦中風治療藥的市場規模在2020年∼2024年間,預測將成長到12億2000萬美元,在預測期間中預計將以5%的年複合成長率增長。

越來越多的中風,採用新型口服抗凝劑(NOAC)以及久坐不動的生活方式的人們推動了市場的發展。

本報告提供全球急性缺血性腦中風治療藥市場調查,提供市場形勢和規模,波特的五力分析,各類型的市場區隔,客戶和各地區形勢,業者情勢,供應商分析等資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

市場區隔:各類型

  • 市場區隔
  • 各類型比較
  • 血栓溶解劑:市場規模與預測(2019年∼2024年)
  • 抗凝固劑:市場規模與預測(2019年∼2024年)
  • 抗血小板治療藥:市場規模與預測(2019年∼2024年)
  • 抗高血壓治療藥:市場規模與預測(2019年∼2024年)
  • 其他治療:市場規模與預測(2019年∼2024年)
  • 各類型的市場機會

客戶形勢

  • 客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美:市場規模與預測(2019年∼2024年)
  • 歐洲:市場規模與預測(2019年∼2024年)
  • 亞洲:市場規模與預測(2019年∼2024年)
  • 其他地區:市場規模與預測(2019年∼2024年)
  • 主要國家
  • 各地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況
  • 競爭模式

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi

附錄

目錄
Product Code: IRTNTR45749

Technavio has been monitoring the acute ischemic stroke therapeutics market and it is poised to grow by $ 1.22 bn during 2020-2024, progressing at a CAGR of 5% during the forecast period. Our reports on the acute ischemic stroke therapeutics market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of stroke, increasing adoption of NOACs, and increasing prevalence of sedentary lifestyles. In addition, the rising prevalence of stroke is anticipated to boost the growth of the market as well.

The acute ischemic stroke therapeutics market analysis includes type segment and geographical landscapes.

Technavio's acute ischemic stroke therapeutics market is segmented as below:

By Type

  • Thrombolytics
  • Anticoagulants
  • Antiplatelets
  • Antihypertensives
  • Other therapeutics

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the TBI, a value-addition in AIS research as one of the prime reasons driving the acute ischemic stroke therapeutics market growth during the next few years. Also, the advent of genomic medicine and a strong pipeline will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our acute ischemic stroke therapeutics market report covers the following areas:

  • Acute ischemic stroke therapeutics market sizing
  • Acute ischemic stroke therapeutics market forecast
  • Acute ischemic stroke therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading acute ischemic stroke therapeutics market vendors that include Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., and Sanofi. Also, the acute ischemic stroke therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Thrombolytics - Market size and forecast 2019-2024
  • Anticoagulants - Market size and forecast 2019-2024
  • Antiplatelets - Market size and forecast 2019-2024
  • Antihypertensives - Market size and forecast 2019-2024
  • Other therapeutics - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer landscape

  • Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive Scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Thrombolytics - Market size and forecast 2019-2024 ($ million)
  • 24: Thrombolytics - Year-over-year growth 2019-2024 (%)
  • 25: Anticoagulants - Market size and forecast 2019-2024 ($ million)
  • 26: Anticoagulants - Year-over-year growth 2019-2024 (%)
  • 27: Antiplatelets - Market size and forecast 2019-2024 ($ million)
  • 28: Antiplatelets - Year-over-year growth 2019-2024 (%)
  • 29: Antihypertensives - Market size and forecast 2019-2024 ($ million)
  • 30: Antihypertensives - Year-over-year growth 2019-2024 (%)
  • 31: Other therapeutics - Market size and forecast 2019-2024 ($ million)
  • 32: Other therapeutics - Year-over-year growth 2019-2024 (%)
  • 33: Market opportunity by Type
  • 34: Customer landscape
  • 35: Market share by geography 2019-2024 (%)
  • 36: Geographic comparison
  • 37: North America - Market size and forecast 2019-2024 ($ million)
  • 38: North America - Year-over-year growth 2019-2024 (%)
  • 39: Europe - Market size and forecast 2019-2024 ($ million)
  • 40: Europe - Year-over-year growth 2019-2024 (%)
  • 41: Asia - Market size and forecast 2019-2024 ($ million)
  • 42: Asia - Year-over-year growth 2019-2024 (%)
  • 43: ROW - Market size and forecast 2019-2024 ($ million)
  • 44: ROW - Year-over-year growth 2019-2024 (%)
  • 45: Key leading countries
  • 46: Market opportunity by geography ($ million)
  • 47: Impact of drivers and challenges
  • 48: Vendor landscape
  • 49: Landscape disruption
  • 50: Industry risks
  • 51: Vendors covered
  • 52: Market positioning of vendors
  • 53: Amgen Inc. - Overview
  • 54: Amgen Inc. - Business segments
  • 55: Amgen Inc. - Key offerings
  • 56: Amgen Inc. - Key customers
  • 57: Amgen Inc. - Segment focus
  • 58: AstraZeneca Plc - Overview
  • 59: AstraZeneca Plc - Product and service
  • 60: AstraZeneca Plc - Key offerings
  • 61: AstraZeneca Plc - Key customers
  • 62: AstraZeneca Plc - Segment focus
  • 63: Bayer AG - Overview
  • 64: Bayer AG - Business segments
  • 65: Bayer AG - Key offerings
  • 66: Bayer AG - Key customers
  • 67: Bayer AG - Segment focus
  • 68: Boehringer Ingelheim International GmbH - Overview
  • 69: Boehringer Ingelheim International GmbH - Business segments
  • 70: Boehringer Ingelheim International GmbH - Key offerings
  • 71: Boehringer Ingelheim International GmbH - Key customers
  • 72: Boehringer Ingelheim International GmbH - Segment focus
  • 73: Bristol-Myers Squibb Co. - Overview
  • 74: Bristol-Myers Squibb Co. - Product and service
  • 75: Bristol-Myers Squibb Co. - Key offerings
  • 76: Bristol-Myers Squibb Co. - Key customers
  • 77: Bristol-Myers Squibb Co. - Segment focus
  • 78: Daiichi Sankyo Co. Ltd. - Overview
  • 79: Daiichi Sankyo Co. Ltd. - Business segments
  • 80: Daiichi Sankyo Co. Ltd. - Key offerings
  • 81: Daiichi Sankyo Co. Ltd. - Key customers
  • 82: Daiichi Sankyo Co. Ltd. - Segment focus
  • 83: F. Hoffmann-La Roche Ltd. - Overview
  • 84: F. Hoffmann-La Roche Ltd. - Business segments
  • 85: F. Hoffmann-La Roche Ltd. - Key offerings
  • 86: F. Hoffmann-La Roche Ltd. - Key customers
  • 87: F. Hoffmann-La Roche Ltd. - Segment focus
  • 88: Merck & Co. Inc. - Overview
  • 89: Merck & Co. Inc. - Business segments
  • 90: Merck & Co. Inc. - Key offerings
  • 91: Merck & Co. Inc. - Key customers
  • 92: Merck & Co. Inc. - Segment focus
  • 93: Pfizer Inc. - Overview
  • 94: Pfizer Inc. - Business segments
  • 95: Pfizer Inc. - Key offerings
  • 96: Pfizer Inc. - Key customers
  • 97: Pfizer Inc. - Segment focus
  • 98: Sanofi - Overview
  • 99: Sanofi - Business segments
  • 100: Sanofi - Key offerings
  • 101: Sanofi - Key customers
  • 102: Sanofi - Segment focus
  • 103: Currency conversion rates for US$
  • 104: Research Methodology
  • 105: Validation techniques employed for market sizing
  • 106: Information sources
  • 107: List of abbreviations